Chengdu Easton Biopharmaceuticals (688513.SH): Injectable YLSH003 initiates Phase I/II clinical trials and completes the enrollment of the first subject.

Chengdu Easton Biopharmaceuticals (688513.SH) announced that its wholly-owned subsidiary, Shanghai Yulo Biotech Co., Ltd. (referred to as "Shanghai Yulo"), has initiated a Phase I/II clinical trial for the injectable YLSH003, a type 1 biopharmaceutical developed independently by the company, for the treatment of advanced solid tumors. The first subject has successfully received the medication recently. YLSH003 is a novel antibody-drug conjugate (ADC) targeting Tissue Factor (TF), intended for the treatment of advanced solid tumors. TF is a transmembrane glycoprotein that serves as the primary initiator of the coagulation process in the body under normal physiological conditions. Studies have shown that high expression of TF in tumors is a major cause of recurrence and metastasis in most late-stage solid tumors.